ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 693

The Utility of a Rise in Anti – Double Stranded DNA Antibodies for Predicting Disease Flares in Systemic Lupus Erythematosus. a Meta-Analysis

Margrét Arna Viktorsdóttir1, Sæmundur Rögnvaldsson1, Þórunn Jónsdóttir2 and Gunnar Tomasson3, 1University of Iceland, Faculty of Medicine, Reykjavík, Iceland, 2Landspítali University Hospital, Reykjavík, Iceland, 3University of Iceland, Faculty of Medicine, Reykjavik, IS

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: anti-dsDNA, meta-analysis and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The ability of predicting disease flares in systemic lupus erythematosus (SLE) by serial measurements of antibodies to double stranded DNA (anti-dsDNA) remains uncertain. Previous studies have found inconsistent results and clinical guidelines provide vague recommendations regarding this aspect of disease management. The objective of this study is to assess the diagnostic value of rise in anti-dsDNA for prediction of a disease flare in SLE.

Methods: A MEDLINE search without language restrictions was conducted to identify papers on anti-dsDNA and disease flares in SLE. Papers that could not be excluded by a review of titles and abstracts were subject to a detailed review. The primary inclusion criteria were 1) availability of the data to extract the sensitivity and specificity of a rise in anti-dsDNA for a disease flare and 2) the rise in anti-dsDNA preceded the flare. For each study, the positive and negative likelihood ratios were calculated and information extracted on disease manifestations and laboratory methods of anti-dsDNA measurements. Summary estimates with 95% confidence intervals (CI) were calculated with a random effects model and results expressed with forest plots. Between-study heterogeneity was assessed with I2, which takes a value from 0 to 1 and refers to the part of the total variability in the meta-analysis that is due to heterogeneity. Meta-regression was used to assess the impact of the i)publication year, ii)gender proportions, iii)proportion of patients who had renal manifestations, iv)method- and v)frequency of anti-dsDNA measurements on summary estimates and heterogeneity. Egger’s test was used to assess for publication bias using p-value of <0.05 as cut-off. The trim-and-fill method was used to adjust the summary estimates for publication bias.

Results:

Literature search identified 1690 papers of which 58 underwent full-text review. Nine studies with a total of 922 patients were included, of them 256 patients had a rise in anti-dsDNA and 243 had flares. Summary estimates for positive and negative likelihood ratios for anti-dsDNA rise and subsequent disease flare were 4.15 (95% CI 2.03-8.47) and 0.47 (95% CI 0.31-0.72) respectively (Figure). There was substantial between-study heterogeneity I2=0.89). Neither disease manifestations nor the methods anti-dsDNA measurements affected the summary estimates or explained heterogeneity. Findings were consistent with presence of publication bias (p=0.021). Adjustment for publication bias substantially attenuated the summary estimates resulting in positive and negative likelihood ratios of 1.90 (95% CI 0.84-4.33) and 0.72 (95% CI 0.46-1.14), respectively.

Conclusion:

A rise in anti-dsDNA has a limited ability for predicting flares in SLE and publication bias may have exaggerated the utility of serial anti-dsDNA measurements. These findings have direct implications for clinical management of SLE.

 


Disclosure: M. A. Viktorsdóttir, None; S. Rögnvaldsson, None; Þ. Jónsdóttir, None; G. Tomasson, None.

To cite this abstract in AMA style:

Viktorsdóttir MA, Rögnvaldsson S, Jónsdóttir Þ, Tomasson G. The Utility of a Rise in Anti – Double Stranded DNA Antibodies for Predicting Disease Flares in Systemic Lupus Erythematosus. a Meta-Analysis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-utility-of-a-rise-in-anti-double-stranded-dna-antibodies-for-predicting-disease-flares-in-systemic-lupus-erythematosus-a-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-utility-of-a-rise-in-anti-double-stranded-dna-antibodies-for-predicting-disease-flares-in-systemic-lupus-erythematosus-a-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology